BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

185 related articles for article (PubMed ID: 33775530)

  • 1. Comprehensive genomic profiling of metastatic collecting duct carcinoma, renal medullary carcinoma, and clear cell renal cell carcinoma.
    Bratslavsky G; Gleicher S; Jacob JM; Sanford TH; Shapiro O; Bourboulia D; Gay LM; Andrea Elvin J; Vergilio JA; Suh J; Ramkissoon S; Severson EA; Killian JK; Schrock AB; Chung JH; Miller VA; Mollapour M; Ross JS
    Urol Oncol; 2021 Jun; 39(6):367.e1-367.e5. PubMed ID: 33775530
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characterization of Clinical Cases of Collecting Duct Carcinoma of the Kidney Assessed by Comprehensive Genomic Profiling.
    Pal SK; Choueiri TK; Wang K; Khaira D; Karam JA; Van Allen E; Palma NA; Stein MN; Johnson A; Squillace R; Elvin JA; Chmielecki J; Yelensky R; Yakirevich E; Lipson D; Lin DI; Miller VA; Stephens PJ; Ali SM; Ross JS
    Eur Urol; 2016 Sep; 70(3):516-21. PubMed ID: 26149668
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comprehensive Genomic Profiling of NF2-Mutated Kidney Tumors Reveals Potential Targets for Therapy.
    Hacking SM; Pavlick D; Wang Y; Carneiro BA; Mullally M; Lu S; Canepa M; Bratslavsky G; Jacob J; Necchi A; Spiess PE; Wang L; Yakirevich E; Ross J
    Oncologist; 2023 Jul; 28(7):e508-e519. PubMed ID: 36917021
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Characterization of Clinical Cases of Advanced Papillary Renal Cell Carcinoma via Comprehensive Genomic Profiling.
    Pal SK; Ali SM; Yakirevich E; Geynisman DM; Karam JA; Elvin JA; Frampton GM; Huang X; Lin DI; Rosenzweig M; Lipson D; Stephens PJ; Ross JS; Miller VA; Agarwal N; Shuch B; Choueiri TK; Chung JH
    Eur Urol; 2018 Jan; 73(1):71-78. PubMed ID: 28592388
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comprehensive Genomic Profiling of Adult Renal Sarcomas Provides Insight into Disease Biology and Opportunities for Targeted Therapies.
    Yakirevich E; Madison R; Fridman E; Mangray S; Carneiro BA; Lu S; Cooke M; Bratslavsky G; Webster J; Ross JS; Ali SM
    Eur Urol Oncol; 2021 Apr; 4(2):282-288. PubMed ID: 31412008
    [TBL] [Abstract][Full Text] [Related]  

  • 6. SMARCB1/INI1 inactivation in renal medullary carcinoma.
    Calderaro J; Moroch J; Pierron G; Pedeutour F; Grison C; Maillé P; Soyeux P; de la Taille A; Couturier J; Vieillefond A; Rousselet MC; Delattre O; Allory Y
    Histopathology; 2012 Sep; 61(3):428-35. PubMed ID: 22686875
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparative Genomic Profiling of Refractory and Metastatic Penile and Nonpenile Cutaneous Squamous Cell Carcinoma: Implications for Selection of Systemic Therapy.
    Jacob JM; Ferry EK; Gay LM; Elvin JA; Vergilio JA; Ramkissoon S; Severson E; Necchi A; Killian JK; Ali SM; Schrock AB; Liu NW; Chung J; Miller VA; Stephens PJ; Welsh A; Corona RJ; Ross JS; Bratslavsky G
    J Urol; 2019 Mar; 201(3):541-548. PubMed ID: 30291913
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Genomic Characterization of Renal Cell Carcinoma with Sarcomatoid Dedifferentiation Pinpoints Recurrent Genomic Alterations.
    Malouf GG; Ali SM; Wang K; Balasubramanian S; Ross JS; Miller VA; Stephens PJ; Khayat D; Pal SK; Su X; Sircar K; Tamboli P; Jonasch E; Tannir NM; Wood CG; Karam JA
    Eur Urol; 2016 Aug; 70(2):348-57. PubMed ID: 26895810
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive Molecular Characterization Identifies Distinct Genomic and Immune Hallmarks of Renal Medullary Carcinoma.
    Msaouel P; Malouf GG; Su X; Yao H; Tripathi DN; Soeung M; Gao J; Rao P; Coarfa C; Creighton CJ; Bertocchio JP; Kunnimalaiyaan S; Multani AS; Blando J; He R; Shapiro DD; Perelli L; Srinivasan S; Carbone F; Pilié PG; Karki M; Seervai RNH; Vokshi BH; Lopez-Terrada D; Cheng EH; Tang X; Lu W; Wistuba II; Thompson TC; Davidson I; Giuliani V; Schlacher K; Carugo A; Heffernan TP; Sharma P; Karam JA; Wood CG; Walker CL; Genovese G; Tannir NM
    Cancer Cell; 2020 May; 37(5):720-734.e13. PubMed ID: 32359397
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Carcinoma of the collecting ducts of Bellini and renal medullary carcinoma: clinicopathologic analysis of 52 cases of rare aggressive subtypes of renal cell carcinoma with a focus on their interrelationship.
    Gupta R; Billis A; Shah RB; Moch H; Osunkoya AO; Jochum W; Hes O; Bacchi CE; de Castro MG; Hansel DE; Zhou M; Vankalakunti M; Salles PG; Cabrera RA; Gown AM; Amin MB
    Am J Surg Pathol; 2012 Sep; 36(9):1265-78. PubMed ID: 22895263
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling.
    Schrock AB; Li SD; Frampton GM; Suh J; Braun E; Mehra R; Buck SC; Bufill JA; Peled N; Karim NA; Hsieh KC; Doria M; Knost J; Chen R; Ou SI; Ross JS; Stephens PJ; Fishkin P; Miller VA; Ali SM; Halmos B; Liu JJ
    J Thorac Oncol; 2017 Jun; 12(6):932-942. PubMed ID: 28315738
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A genomic mutation spectrum of collecting duct carcinoma in the Chinese population.
    Zhang H; Lu X; Huang G; Hua M; Zhang W; Wang T; Huang L; Wang Z; Chen Q; Li J; Yang Q; Yang G
    BMC Med Genomics; 2022 Jan; 15(1):1. PubMed ID: 34980126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Genomic Alterations of Renal Cell Carcinoma and Clinical Implications in the Chinese Population.
    Zhang S; Wang B; Zhang F; Ye J; Ge L; Ma L
    Med Sci Monit; 2019 Apr; 25():2959-2965. PubMed ID: 31007253
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma.
    Attalla K; DiNatale RG; Rappold PM; Fong CJ; Sanchez-Vega F; Silagy AW; Weng S; Coleman J; Lee CH; Carlo MI; Durack JC; Solomon SB; Reuter VE; Russo P; Chan TA; Motzer RJ; Schultz ND; Reznik E; Voss MH; Hakimi AA
    Clin Cancer Res; 2021 Oct; 27(20):5595-5606. PubMed ID: 34261695
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reappraisal of Morphologic Differences Between Renal Medullary Carcinoma, Collecting Duct Carcinoma, and Fumarate Hydratase-deficient Renal Cell Carcinoma.
    Ohe C; Smith SC; Sirohi D; Divatia M; de Peralta-Venturina M; Paner GP; Agaimy A; Amin MB; Argani P; Chen YB; Cheng L; Colecchia M; Compérat E; Werneck da Cunha I; Epstein JI; Gill AJ; Hes O; Hirsch MS; Jochum W; Kunju LP; Maclean F; Magi-Galluzzi C; McKenney JK; Mehra R; Nesi G; Osunkoya AO; Picken MM; Rao P; Reuter VE; de Oliveira Salles PG; Schultz L; Tickoo SK; Tomlins SA; Trpkov K; Amin MB
    Am J Surg Pathol; 2018 Mar; 42(3):279-292. PubMed ID: 29309300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. "Renal Cell Carcinoma With Leiomyomatous Stroma" Harbor Somatic Mutations of TSC1, TSC2, MTOR, and/or ELOC (TCEB1): Clinicopathologic and Molecular Characterization of 18 Sporadic Tumors Supports a Distinct Entity.
    Shah RB; Stohr BA; Tu ZJ; Gao Y; Przybycin CG; Nguyen J; Cox RM; Rashid-Kolvear F; Weindel MD; Farkas DH; Trpkov K; McKenney JK
    Am J Surg Pathol; 2020 May; 44(5):571-581. PubMed ID: 31850909
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeted genomic landscape of metastases compared to primary tumours in clear cell metastatic renal cell carcinoma.
    de Velasco G; Wankowicz SA; Madison R; Ali SM; Norton C; Duquette A; Ross JS; Bossé D; Lalani AA; Miller VA; Stephens PJ; Young L; Hakimi AA; Signoretti S; Pal SK; Choueiri TK
    Br J Cancer; 2018 May; 118(9):1238-1242. PubMed ID: 29674707
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative Genomic Profiling of Matched Primary and Metastatic Tumors in Renal Cell Carcinoma.
    Becerra MF; Reznik E; Redzematovic A; Tennenbaum DM; Kashan M; Ghanaat M; Casuscelli J; Manley B; Jonsson P; DiNatale RG; Blum KA; Durack JC; Solomon SB; Arcila ME; Bourque C; Socci N; Carlo MI; Lee CH; Voss MH; Feldman DR; Motzer RJ; Coleman JA; Russo P; Cheng EH; Hakimi AA; Hsieh JJ
    Eur Urol Focus; 2018 Dec; 4(6):986-994. PubMed ID: 29066084
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Genomically annotated risk model for advanced renal-cell carcinoma: a retrospective cohort study.
    Voss MH; Reising A; Cheng Y; Patel P; Marker M; Kuo F; Chan TA; Choueiri TK; Hsieh JJ; Hakimi AA; Motzer RJ
    Lancet Oncol; 2018 Dec; 19(12):1688-1698. PubMed ID: 30416077
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genomic Biomarkers of a Randomized Trial Comparing First-line Everolimus and Sunitinib in Patients with Metastatic Renal Cell Carcinoma.
    Hsieh JJ; Chen D; Wang PI; Marker M; Redzematovic A; Chen YB; Selcuklu SD; Weinhold N; Bouvier N; Huberman KH; Bhanot U; Chevinsky MS; Patel P; Pinciroli P; Won HH; You D; Viale A; Lee W; Hakimi AA; Berger MF; Socci ND; Cheng EH; Knox J; Voss MH; Voi M; Motzer RJ
    Eur Urol; 2017 Mar; 71(3):405-414. PubMed ID: 27751729
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.